The Gujarat-based company Meril Life Sciences approached government for price exemption under the Drug Price Control Order of 2013.
The company states that the DPCO 2013 order is not applicable when a new drug is developed through a unique, indigenous process and there could be exemption granted up to five years. (Representational Image)
Hyderabad: The first indigenous bio-resorbable coronary stent MeRes 100 has applied to the expert committee of the National Pharmaceutical Pricing Authority for exemption from the government’s notified price ceiling for stents.
The Gujarat-based company Meril Life Sciences approached government for price exemption under the Drug Price Control Order of 2013.
The company states that the DPCO 2013 order is not applicable when a new drug is developed through a unique, indigenous process and there could be exemption granted up to five years. NAPPA authorities have referred their proposal to an expert panel.
( Source : Deccan Chronicle. )
Next Story
